The survival rate comparison of non small cell lung carcinoma patients who are given by epidermal growth factor receptor-tyrosin kinase inhibitor and those given by first-line chemotherapy treatment. (2022). Nusantara Medical Science Journal, 6(2), 103-115. https://doi.org/10.20956/nmsj.v6i2.18857